Related Experiment Video
Updated: Jan 30, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
Botulinum toxin blocks mast cells and prevents rosacea like inflammation
Jae Eun Choi1, Tyler Werbel2, Zhenping Wang1
1Department of Dermatology, University of California, San Diego, CA, USA.
Background:
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.
Objectives:
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.
Methods:
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.
Results:
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.
Conclusions:
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study.
Insights
Onabotulinum toxin (Botox) directly inhibits mast cell degranulation, a key factor in rosacea. This finding supports Botox as a potential therapy for severe rosacea.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Rosacea is a chronic inflammatory skin condition.
- Mast cells and cathelicidin LL-37 are implicated in rosacea etiology.
- Onabotulinum toxin shows clinical benefit in refractory rosacea, but its mechanism is unclear.
Purpose of the Study:
- To elucidate the molecular mechanism of onabotulinum toxin in improving rosacea lesions.
- To investigate the direct effects of onabotulinum toxin on mast cells.
Main Methods:
- Human and murine mast cells were treated with onabotulinum toxin A or B.
- Mast cell degranulation was assessed via beta-hexosaminidase activity.
- In vivo rosacea models were established using LL-37 and onabotulinum toxin A.
- Expression of botulinum toxin receptor Sv2, SNAP-25, and VAMP2 was analyzed.
Main Results:
- Onabotulinum toxin A and B inhibited mast cell degranulation in vitro.
- Onabotulinum toxin A and B altered SNAP-25 and VAMP2 expression in mast cells.
- In vivo, onabotulinum toxin A reduced LL-37-induced erythema, mast cell degranulation, and rosacea biomarkers.
Conclusions:
- Onabotulinum toxin directly inhibits mast cell degranulation, reducing rosacea inflammation.
- Onabotulinum toxin may be an effective treatment for refractory rosacea.
- Further research into onabotulinum toxin for rosacea is warranted.
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Inflammation
Types of Toxins
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
Cancer Prevention
Some...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Block Diagram Reduction
The first step in this process is the identification and relocation of a branch point. A branch point, where a...

